OGN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on: 
Wednesday, March 1, 2023
NYSE, OGN, Organon & Co., Organon, News, Cryptocurrency, Private investigator

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points: 
  • NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health

Retrieved on: 
Monday, February 27, 2023
International Women's Day, Diagnosis, Menopause, NYSE, Organization, Woman, Partnership, Research, OGN, Culture, Government, Gender, Human resources, AWHF, Medicine, International Women's Health Coalition, Friends, Endometriosis, Taboo, Health, Women's health, Light, Pharmaceutical industry, Nursing, Birth control, Organon, QC

KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.

Key Points: 
  • KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.
  • In fact, only 24% of women felt their physician is very knowledgeable about gynecological and reproductive health.
  • With Organon Canada's support and leadership, we can truly make a meaningful difference in the name of women's health.
  • For further insights and to view additional data from the Alberta Women's Health Foundation survey, visit albertawomenshealthfoundation.org/our-impact .

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

Retrieved on: 
Monday, February 6, 2023
Pharmaceutical, Health, Women, Consumer, OGN, ID, EST, Interest, NYSE, Webcast, Security (finance), Organon

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
  • Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk .

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on: 
Monday, February 13, 2023
Knowledge, International Women's Day, International Women's Health Coalition, Mother, Woman, Bleeding, Government, Sleep, Menopause, MMR, Abdominal pain, NYSE, Workplace, MENAT, Maternal health, Endometriosis, Health, Research, Mortality, Association of British HealthTech Industries, Associate, Pregnancy, Femtech, OGN, Light, Hypertension, Prevalence, UNICEF, Death, Infection, Hot, Pharmaceutical industry, Dietary supplement, Birth control, Organon

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points: 
  • Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
  • Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
  • We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
  • Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on: 
Monday, February 13, 2023
Knowledge, International Women's Day, International Women's Health Coalition, Mother, Woman, Bleeding, Government, Sleep, Menopause, MMR, Abdominal pain, NYSE, Workplace, MENAT, Maternal health, Endometriosis, Health, Research, Mortality, Association of British HealthTech Industries, Associate, Pregnancy, Femtech, OGN, Light, Hypertension, Prevalence, UNICEF, Death, Infection, Hot, Pharmaceutical industry, Dietary supplement, Birth control, Organon

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points: 
  • Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
  • Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
  • We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
  • Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy

Retrieved on: 
Thursday, January 5, 2023
Women, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Health Technology, Consumer, Food, Research, Knowledge, OGN, Patient, NYSE, Physician, Health, Woman, Step, Pharmaceutical industry, Organon

Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
  • The agreement also grants Organon the option to acquire Claria Medical.
  • “Collaborations such as our agreement with Claria Medical are integral to our business development approach.
  • Alexey Salamini, Claria Medical’s CEO, commented, “Our team is excited to enter this strategic agreement with Organon, who brings extensive knowledge in women’s health.

Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 15, 2022
Health, Consumer, Women, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, OGN, NYSE, Health, Woman, Investment, Conference, Organon

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, 2023 at 7:30 a.m. PT.

Key Points: 
  • Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, 2023 at 7:30 a.m. PT.
  • Organon is a global healthcare company formed to focus on improving the health of women throughout their lives.
  • Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary

Retrieved on: 
Monday, December 12, 2022
Vitamins, Supplements, General Health, Pharmaceutical, Health, MSD, Security (finance), Corporation, College, Commercial, Pennsylvania Office of General Counsel, General counsel, Employment, NYSE, Woman, Investment, Senior, Multimedia, OGN, Merck, Health, Ethics, Yale Law School, Management, Organon

Organon (NYSE: OGN), a global womens healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organons executive leadership team, effective January 1, 2023.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organons executive leadership team, effective January 1, 2023.
  • Mr. Weaver was named as the interim head of the Office of General Counsel and Corporate Secretary in July 2022.
  • Prior to serving as interim General Counsel and Corporate Secretary, Mr. Weaver served as Senior Vice President, Commercial, Regulatory, Securities, Employment and Deputy Corporate Secretary at Organon.
  • I am excited to continue to lead Organons Office of General Counsel as we build a company to serve an important purpose in womens health, said Kirke Weaver.

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 15, 2022
Health, Consumer, Women, Managed Care, General Health, Pharmaceutical, Biotechnology, Investment, EST, OGN, Woman, Piper Sandler Companies, Conference, Health, NYSE, Pharmaceutical industry, Organon

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
  • Organon is a global healthcare company formed to focus on improving the health of women throughout their lives.
  • Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
Health, Consumer, Women, Managed Care, General Health, Pharmaceutical, Biotechnology, EDT, NYSE, Interest, Health, Webcast, Woman, ID, OGN, Investment, Organon

Organon (NYSE: OGN), a global womens healthcare company will release its third quarter 2022 financial results on November 3, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company will release its third quarter 2022 financial results on November 3, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the companys website.
  • Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 58511-502 and by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk .